Exact HCC assay significantly better than SOC

Exact Sciences Corp. (NASDAQ:EXAS) reported data showing that its hepatocellular carcinoma blood test had greater sensitivity and specificity in identifying HCC, especially early stage cancer, vs. the standard of care alpha fetoprotein (AFP) test.

The

Read the full 342 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE